Company profile
ALTERITY THERAPEUTICS LTD
NASDAQ:ATHEBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PBT-434 | phase2 | — | 2 | completed, not_yet_recruiting |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05864365 | phase2 | completed | 2023-05-23 | 2025-02-26 | Alterity Therapeutics | A Biomarker Study of ATH434 in Participants With MSA |
| NCT07729852 | phase2 | not_yet_recruiting | 2026-07-01 | 2029-07-01 | Alterity Therapeutics | Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France |
| NCT05109091 | phase2 | completed | 2022-07-01 | 2024-11-28 | Alterity Therapeutics | Study of ATH434 in Participants with Multiple System Atrophy |
FDA applications (0)
No records yet.